ABT Healthcare

Abbott Laboratories

$109.40-0.69%

Price as of close on Nov 3, 2026 · Financials updated Oct 6, 2026

Basics

Sector: Healthcare
Industry: Medical Devices
Country: United States
Market cap: 189.3B USD
Enterprise value: 208.5B USD
Full-time employees: 122,000

Overall health

Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: higher risk than most peers: less short-term liquidity (current ratio 1.38 vs a peer median of 2.59) and more debt relative to equity (0.64× vs a peer median of 0.22×)higher risk: less liquidity (current ratio 1.38 vs peers 2.59) and more debt vs equity (0.64× vs peers 0.22×)
About average: valuation

Ranks #733 of 1,157 healthcare companies (bottom 37%)

See how it ranks against its peers

Worth knowing

Stock pay is large next to buybacks. Stock-based pay expense $2.0B vs $3.4B spent repurchasing shares over the 3 fiscal years to 2025.
Over three fiscal years Abbott Laboratories recorded $2.0B of stock-based pay expense and spent $3.4B repurchasing shares (repurchases can include shares withheld to cover employees' taxes).Over three fiscal years Abbott Laboratories recorded $2.0B of stock-based pay expense and spent $3.4B repurchasing shares.
Profit is backed by cash. Free cash flow is 144% of reported profit.
Abbott Laboratories's free cash flow is 144% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.

StockQuotient Score

45/ 100

Oct 5 46 → Nov 4 45 (-1)

Valuation

Is the price right?

57/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Helped by:

▲ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield2.9%

SEC filings · 12 months to Jun 2026Reported value30% base weight · Z-score 0.94Sector median: 0.0148 · MAD: 0.0148

EBITDA yield5.0%

SEC filings · 12 months to Jun 2026Reported value50% base weight · Z-score 0.24Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield4.1%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield27.0%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

26/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 3.2%

Why

Weaker than most peers on:

▼ EPS growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growth-61.0%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -2.36Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth5.0%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score -0.10Sector median: 0.0584 · MAD: 0.0840

Revenue growth8.1%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.20Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

68/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Operating margin
▲ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin15.8%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.72Sector median: 0.0706 · MAD: 0.1217

Return on assets5.0%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.62Sector median: 0.0166 · MAD: 0.0537

Return on invested capital7.4%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.27Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin56.6%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity10.6%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Current ratio
▼ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.58

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score 0.12Sector median: 0.6250 · MAD: 0.3380

Current ratio1.38×

SEC filings · latest balance sheetReported value33% base weight · Z-score -0.87Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.64×

SEC filings · latest balance sheetReported value33% base weight · Z-score -2.04Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Abbott Laboratories

Is Abbott Laboratories getting weaker?: Its latest SEC filing (Jul 28, 2026) showed no major changes. Its overall score is unchanged at 45/100 since Oct 28, 2026.
How is Abbott Laboratories valued vs its peers?: Priced about in line with its peers. Valuation scores 57/100 against 1,393 healthcare peers. Earnings yield 2.9% vs a peer median of 1.5% (stronger than 61% of peers).Earnings yield 2.9% vs peers 1.5% (stronger than 61% of peers).
Is Abbott Laboratories growing?: More slowly than most of its peers. Growth scores 26/100 against 1,393 healthcare peers. Earnings per share growth -61.0% vs a peer median of 9.8% (weaker than 94% of peers).Earnings per share growth -61.0% vs peers 9.8% (weaker than 94% of peers).
How profitable is Abbott Laboratories?: More profitable than most of its peers. Profitability scores 68/100 against 1,393 healthcare peers. Operating margin 15.8% vs a peer median of 7.1% (stronger than 73% of peers).Operating margin 15.8% vs peers 7.1% (stronger than 73% of peers).
How risky is Abbott Laboratories?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 1.38× vs a peer median of 2.59× (weaker than 78% of peers).Current ratio 1.38× vs peers 2.59× (weaker than 78% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Jul 28, 2026 · compared with the quarter ended Mar 31, 2026

No major changes

	Previous quarter	Latest quarter	Change
Revenue (12 months)	45.1B USD	46.6B USD	+3.2%
Net income (12 months)	6.3B USD	5.4B USD	−13.6%
Operating margin	17.1%	15.8%	−1.3 pts
Free cash flow (12 months)	7.4B USD	7.8B USD	+6.0%
Debt	34.0B USD	32.6B USD	−4.2%
Cash	6.8B USD	5.1B USD	−25.0%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Medical Devices · 33 companies

Valuations in Medical Devices are near the bottom of their range since 2016.

7% of months since 2016 were valued lower than now.
4% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values −8% and earnings +33% (medians): earnings grew faster than prices.
Median price-to-sales is +20% vs the whole market, against a usual +109%.

2016Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	57.0%	56.1%	55.2%	55.4%	56.4%	▲ 1.0 pts
Operating margin	19.6%	19.2%	16.2%	16.3%	18.2%	▲ 1.9 pts
Net margin	16.4%	15.9%	14.3%	31.9%	14.7%	▼ 17 pts
Return on assets (ROA)	9.4%	9.3%	7.8%	16.5%	7.5%	▼ 8.9 pts
Return on equity (ROE)	19.8%	18.9%	14.8%	28.1%	12.5%	▼ 16 pts
Free cash flow margin	20.1%	17.9%	12.6%	15.1%	16.7%	▲ 1.5 pts
Current ratio	1.85×	1.63×	1.64×	1.67×	1.58×	▼ 5.7%
Quick ratio	1.46×	1.23×	1.16×	1.23×	1.18×	▼ 4.1%
Debt to equity	0.50×	0.46×	0.38×	0.30×	0.25×	▼ 16%
Interest coverage	15.81×	14.99×	10.17×	12.21×	16.33×	▲ 34%

ABT price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: higher risk than most peers: less short-term liquidity (current ratio 1.38 vs a peer median of 2.59) and more debt relative to equity (0.64× vs a peer median of 0.22×)higher risk: less liquidity (current ratio 1.38 vs peers 2.59) and more debt vs equity (0.64× vs peers 0.22×)

About average: valuation

Ranks #733 of 1,157 healthcare companies (bottom 37%)

See how it ranks against its peers

Worth knowing

Stock pay is large next to buybacks. Stock-based pay expense $2.0B vs $3.4B spent repurchasing shares over the 3 fiscal years to 2025.

Over three fiscal years Abbott Laboratories recorded $2.0B of stock-based pay expense and spent $3.4B repurchasing shares (repurchases can include shares withheld to cover employees' taxes).Over three fiscal years Abbott Laboratories recorded $2.0B of stock-based pay expense and spent $3.4B repurchasing shares.

Profit is backed by cash. Free cash flow is 144% of reported profit.

Abbott Laboratories's free cash flow is 144% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.

Questions investors ask about Abbott Laboratories

Is Abbott Laboratories getting weaker?

Its latest SEC filing (Jul 28, 2026) showed no major changes. Its overall score is unchanged at 45/100 since Oct 28, 2026.

How is Abbott Laboratories valued vs its peers?

Priced about in line with its peers. Valuation scores 57/100 against 1,393 healthcare peers. Earnings yield 2.9% vs a peer median of 1.5% (stronger than 61% of peers).Earnings yield 2.9% vs peers 1.5% (stronger than 61% of peers).

Is Abbott Laboratories growing?

More slowly than most of its peers. Growth scores 26/100 against 1,393 healthcare peers. Earnings per share growth -61.0% vs a peer median of 9.8% (weaker than 94% of peers).Earnings per share growth -61.0% vs peers 9.8% (weaker than 94% of peers).

How profitable is Abbott Laboratories?

More profitable than most of its peers. Profitability scores 68/100 against 1,393 healthcare peers. Operating margin 15.8% vs a peer median of 7.1% (stronger than 73% of peers).Operating margin 15.8% vs peers 7.1% (stronger than 73% of peers).

How risky is Abbott Laboratories?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 1.38× vs a peer median of 2.59× (weaker than 78% of peers).Current ratio 1.38× vs peers 2.59× (weaker than 78% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

45.1B USD

46.6B USD

+3.2%

Net income (12 months)

6.3B USD

5.4B USD

−13.6%

Operating margin

17.1%

15.8%

−1.3 pts

Free cash flow (12 months)

7.4B USD

7.8B USD

+6.0%

Debt

34.0B USD

32.6B USD

−4.2%

Cash

6.8B USD

5.1B USD

−25.0%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

57.0%

56.1%

55.2%

55.4%

56.4%

▲ 1.0 pts

Operating margin

19.6%

19.2%

16.2%

16.3%

18.2%

▲ 1.9 pts

Net margin

16.4%

15.9%

14.3%

31.9%

14.7%

▼ 17 pts

Return on assets (ROA)

9.4%

9.3%

7.8%

16.5%

7.5%

▼ 8.9 pts

Return on equity (ROE)

19.8%

18.9%

14.8%

28.1%

12.5%

▼ 16 pts

Free cash flow margin

20.1%

17.9%

12.6%

15.1%

16.7%

▲ 1.5 pts

Current ratio

1.85×

1.63×

1.64×

1.67×

1.58×

▼ 5.7%

Quick ratio

1.46×

1.23×

1.16×

1.23×

1.18×

▼ 4.1%

Debt to equity

0.50×

0.46×

0.38×

0.30×

0.25×

▼ 16%

Interest coverage

15.81×

14.99×

10.17×

12.21×

16.33×

▲ 34%